EP1218411A4 - Secreted proteins and uses thereof - Google Patents

Secreted proteins and uses thereof

Info

Publication number
EP1218411A4
EP1218411A4 EP00965288A EP00965288A EP1218411A4 EP 1218411 A4 EP1218411 A4 EP 1218411A4 EP 00965288 A EP00965288 A EP 00965288A EP 00965288 A EP00965288 A EP 00965288A EP 1218411 A4 EP1218411 A4 EP 1218411A4
Authority
EP
European Patent Office
Prior art keywords
secreted proteins
secreted
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00965288A
Other languages
German (de)
French (fr)
Other versions
EP1218411A2 (en
Inventor
Susan J Kirst
John D Sharp
Christopher C Fraser
Thomas Barnes
Gillian Kingsbury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of EP1218411A2 publication Critical patent/EP1218411A2/en
Publication of EP1218411A4 publication Critical patent/EP1218411A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP00965288A 1999-09-20 2000-09-20 Secreted proteins and uses thereof Withdrawn EP1218411A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39972399A 1999-09-20 1999-09-20
US399723 1999-09-20
PCT/US2000/025982 WO2001021631A2 (en) 1999-09-20 2000-09-20 Secreted proteins and uses thereof

Publications (2)

Publication Number Publication Date
EP1218411A2 EP1218411A2 (en) 2002-07-03
EP1218411A4 true EP1218411A4 (en) 2004-09-01

Family

ID=23580710

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00965288A Withdrawn EP1218411A4 (en) 1999-09-20 2000-09-20 Secreted proteins and uses thereof

Country Status (3)

Country Link
EP (1) EP1218411A4 (en)
AU (1) AU7602400A (en)
WO (1) WO2001021631A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2389722A1 (en) * 1999-11-09 2001-05-17 Human Genome Sciences, Inc. 15 human secreted proteins
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CA2448123C (en) * 2001-05-24 2012-09-11 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
LT2397156T (en) 2005-06-08 2017-02-27 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1)pathway
JP5713377B2 (en) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート Natural antisense and non-coding RNA transcripts as drug targets
CN102282265B (en) 2008-11-28 2020-07-24 埃默里大学 Methods for treating infectious diseases and tumors
CN102317458B (en) 2008-12-04 2018-01-02 库尔纳公司 Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
WO2010065787A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
CN102245640B (en) 2008-12-09 2014-12-31 霍夫曼-拉罗奇有限公司 Anti-PD-L1 antibodies and their use to enhance T-cell function
CA2752239C (en) * 2009-02-12 2021-03-30 Opko Curna, Llc Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
JP5766126B2 (en) 2009-02-12 2015-08-19 クルナ・インコーポレーテッド Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by suppression of natural antisense transcripts against BDNF
CN102482677B (en) 2009-03-16 2017-10-17 库尔纳公司 Nuclear factor (red blood cell derives 2) sample 2 (NRF2) relevant disease is treated by suppressing NRF2 natural antisense transcript
CN102549159B (en) 2009-03-17 2016-08-10 库尔纳公司 By suppressing to treat the disease that DLK1 is correlated with for the natural antisense transcript of δ sample 1 congener (DLK1)
WO2010129799A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
ES2609655T3 (en) 2009-05-06 2017-04-21 Curna, Inc. Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP
WO2010129861A2 (en) 2009-05-08 2010-11-11 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
EP2432881B1 (en) 2009-05-18 2017-11-15 CuRNA, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
WO2010135695A2 (en) 2009-05-22 2010-11-25 Curna, Inc. TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
ES2618576T3 (en) 2009-05-28 2017-06-21 Curna, Inc. Treatment of diseases related to an antiviral gene by inhibiting a natural antisense transcript to an antiviral gene
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
JP6128846B2 (en) 2009-06-16 2017-05-17 クルナ・インコーポレーテッド Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1)
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CA2768947C (en) 2009-07-24 2018-06-19 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
CA2769665A1 (en) 2009-08-05 2011-02-10 Opko Curna, Llc Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
ES2599986T3 (en) 2009-08-11 2017-02-06 Curna, Inc. Treatment of adiponectin-related diseases (ADIPOQ) by inhibiting a natural antisense transcript of an adiponectin (ADIPOQ)
EP2982755B1 (en) 2009-08-21 2020-10-07 CuRNA, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
KR101892760B1 (en) 2009-08-25 2018-08-28 큐알엔에이, 인크. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
CA2775111C (en) 2009-09-25 2019-12-31 Opko Curna, Llc Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
NO2513310T3 (en) 2009-12-16 2018-03-31
US9068183B2 (en) 2009-12-23 2015-06-30 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
CN102869776B (en) 2009-12-23 2017-06-23 库尔纳公司 HGF relevant diseases are treated by suppressing the natural antisense transcript of HGF (HGF)
CA2785173A1 (en) 2009-12-29 2011-07-28 Curna, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
KR101853508B1 (en) 2009-12-29 2018-06-20 큐알엔에이, 인크. TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
ES2677044T3 (en) 2009-12-31 2018-07-27 Curna, Inc. Treatment of diseases related to insulin receptor substrate 2 (IRS2) by inhibition of natural antisense transcript for IRS2 and transcription factor E3 (TFE3)
US8946181B2 (en) 2010-01-04 2015-02-03 Curna, Inc. Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
RU2612161C2 (en) 2010-01-06 2017-03-02 Курна, Инк. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to pancreatic developmental gene
WO2011085347A2 (en) 2010-01-11 2011-07-14 Opko Curna, Llc Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
CN102782135A (en) 2010-01-25 2012-11-14 库尔纳公司 Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1
CA2790506A1 (en) 2010-02-22 2011-08-25 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
CN102869777B (en) 2010-04-02 2018-11-02 库尔纳公司 CSF3 relevant diseases are treated by inhibiting the natural antisense transcript of colony stimulating factor 3 (CSF3)
TWI644675B (en) 2010-04-09 2018-12-21 可娜公司 Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
CN107988228B (en) 2010-05-03 2022-01-25 库尔纳公司 Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to Sirtuin (SIRT)
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
DK2576784T3 (en) 2010-05-26 2018-02-26 Curna Inc TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA
DK2576783T3 (en) 2010-05-26 2018-03-12 Curna Inc TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
CA2803882C (en) 2010-06-23 2022-10-18 Opko Curna, Llc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
NO2593547T3 (en) 2010-07-14 2018-04-14
RU2624048C2 (en) 2010-10-06 2017-06-30 Курна, Инк. Treatment of diseases associated with the sialidase 4 (neu4) gene, by gene neu4 natural antisense transcript inhibition
JP6049623B2 (en) 2010-10-22 2016-12-21 カッパーアールエヌエー，インコーポレイテッド Treatment of IDUA-related diseases by inhibition of natural antisense transcripts to α-L-iduronidase (IDUA)
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
JP6071893B2 (en) 2010-11-23 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Treatment of NANOG-related diseases by inhibition of natural antisense transcripts to NANOG
CN103620036B (en) 2011-06-09 2016-12-21 库尔纳公司 FXN relevant disease is treated by the natural antisense transcript of suppression Frataxin (FXN)
KR101991980B1 (en) 2011-09-06 2019-06-21 큐알엔에이, 인크. TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
ES2694592T3 (en) 2012-03-15 2018-12-21 Curna, Inc. Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of the natural antisense transcript of BDNF
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041284A1 (en) * 1998-02-11 1999-08-19 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999042470A1 (en) * 1998-02-18 1999-08-26 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
EP1130094A2 (en) * 1999-07-08 2001-09-05 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
WO2001075067A2 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046643A1 (en) * 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041284A1 (en) * 1998-02-11 1999-08-19 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999042470A1 (en) * 1998-02-18 1999-08-26 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
EP1130094A2 (en) * 1999-07-08 2001-09-05 Helix Research Institute Primers for synthesizing full length cDNA clones and their use
WO2001075067A2 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CELIS J E ET AL: "SECRETED PROTEINS FROM NORMAL AND SV40 TRANSFORMED HUMAN MRC-5 FIBROBLASTS: TOWARD ESTABLISHING A DATABASE OF HUMAN SECRETED PROTEINS", LEUKEMIA, MACMILLAN PRESS LTD, US, vol. 1, no. 10, October 1987 (1987-10-01), pages 707 - 717, XP001118789, ISSN: 0887-6924 *
HALVORSEN Y-D C ET AL: "Adipose as an endocrine organ: The characterization of secreted proteins from human cultured adipocytes", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 13, no. 4 part 11, 12 March 1999 (1999-03-12), pages A369, XP002146933, ISSN: 0892-6638 *
See also references of WO0121631A3 *

Also Published As

Publication number Publication date
WO2001021631A2 (en) 2001-03-29
AU7602400A (en) 2001-04-24
WO2001021631A3 (en) 2001-11-22
EP1218411A2 (en) 2002-07-03

Similar Documents

Publication Publication Date Title
EP1218411A4 (en) Secreted proteins and uses thereof
EP1175438A4 (en) 62 human secreted proteins
EP1165827A4 (en) 45 human secreted proteins
EP1140976A4 (en) Secreted proteins and uses thereof
EP1159284A4 (en) 33 human secreted proteins
AU6394400A (en) Secreted proteins and uses thereof
AU2002211220A1 (en) Secreted proteins and their uses
EP1189938A4 (en) Secreted proteins and uses thereof
AU5907800A (en) Membrane-associated and secreted proteins and uses thereof
EP1173477A4 (en) 49 human secreted proteins
EP1179000A4 (en) Secreted proteins and uses thereof
AU2001290551A1 (en) Secreted proteins and their uses
EP1165602A4 (en) 49 human secreted proteins
EP1144614A4 (en) 33 human secreted proteins
EP1169332A4 (en) 49 human secreted proteins
EP1171460A4 (en) 48 human secreted proteins
EP1165828A4 (en) 50 human secreted proteins
WO2000069885A8 (en) Secreted proteins and uses thereof
AU1190801A (en) Secreted proteins and uses thereof
EP1159413A4 (en) Secreted proteins and uses thereof
EP1159287A4 (en) 50 human secreted proteins
EP1171626A4 (en) 50 human secreted proteins
EP1165123A4 (en) 48 human secreted proteins
EP1165591A4 (en) 47 human secreted proteins
AU5907200A (en) Secreted proteins and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020410

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SHARP, JOHN, D.

Inventor name: KIRST, SUSAN, J.

Inventor name: FRASER, CHRISTOPHER, C.

Inventor name: KINGSBURY, GILLIAN

Inventor name: BARNES, THOMAS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KINGSBURY, GILLIAN

Inventor name: KIRST, SUSAN, J.

Inventor name: SHARP, JOHN, D.

Inventor name: BARNES, THOMAS

Inventor name: FRASER, CHRISTOPHER, C.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/63 B

Ipc: 7C 12P 21/02 B

Ipc: 7C 12N 1/21 B

Ipc: 7C 07K 14/705 A

Ipc: 7C 07K 14/47 B

Ipc: 7C 07H 21/04 B

A4 Supplementary search report drawn up and despatched

Effective date: 20040719

17Q First examination report despatched

Effective date: 20070326

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070807